Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Agios Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Agios Pharmaceuticals's price to sales ratio was 19.9× on Nov 11, 2026, against 38.0× a year earlier. Over the last 5 years it ranged from 18.5× to 241.7×, with a median of 57.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 19.9× | −15.5 |
| 2025 | Dec 31, 2025 | 35.4× | −21.6 |
| 2024 | Dec 31, 2024 | 57.0× | +5.2 |
| 2023 | Dec 29, 2023 | 51.8× | −103.4 |
| 2022 | Dec 30, 2022 | 155.2× | +114.4 |
| 2021 | Dec 31, 2021 | 40.8× | +25.4 |
| 2020 | Dec 31, 2020 | 15.4× | −9.6 |
| 2019 | Dec 31, 2019 | 25.0× | −11.2 |
| 2018 | Dec 31, 2018 | 36.2× | −13.6 |
| 2017 | Dec 29, 2017 | 49.8× | +17.0 |
| 2016 | Dec 30, 2016 | 32.8× | −3.4 |
| 2015 | Dec 31, 2015 | 36.1× | −31.4 |
| 2014 | Dec 31, 2014 | 67.5× | +37.9 |
| 2013 | Dec 31, 2013 | 29.7× | – |
See a number that looks wrong?